Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011
Sat, August 20, 2011
Fri, August 19, 2011
Thu, August 18, 2011
Wed, August 17, 2011
[ Wed, Aug 17th 2011 ] - Market Wire
PPD???????BioDuro?????
Tue, August 16, 2011
Mon, August 15, 2011
Fri, August 12, 2011
Thu, August 11, 2011
Wed, August 10, 2011
Tue, August 9, 2011
Mon, August 8, 2011
Sun, August 7, 2011
Sat, August 6, 2011
Fri, August 5, 2011

POZEN to Present at the 2011 Stifel Nicolaus Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. -2011-stifel-nicolaus-healthcare-conference.html
Published in Health and Fitness on Wednesday, August 24th 2011 at 4:46 GMT by Market Wire   Print publication without navigation


CHAPEL HILL, N.C.--([ BUSINESS WIRE ])--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that [ Elizabeth Cermak ], the Companya™s Executive Vice President and Chief Commercial Officer, will present at the 2011 Stifel Nicolaus Healthcare Conference on Wednesday, September 7, 2011 at 1:30 p.m. (ET), at the Four Seasons Hotel in Boston. Ms. Cermaka™s presentation will be webcast and available for replay on POZENa™s home page at [ www.pozen.com ].

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years a" something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit [ www.pozen.com ].


Publication Contributing Sources